Why Bio-Path Stock Is Soaring
Why Bio-Path Stock Is Soaring
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.
Bio-Path Holdings, Inc.（纳斯达克股票代码：BPTH）周四股价走高，此前该公司宣布完成了评估 BP1002 治疗难治性/复发急性髓系白血病患者的能力的 BP1002 1/1b期临床试验中的第二剂疫苗。
The Details:
细节：
BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Bio-Path said BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
BP1002 靶向蛋白 Bcl-2，该蛋白负责推动多达 60% 的癌症的细胞存活。Bio-Path 表示，BP1002 可能会克服和预防一些影响 venetoclax 治疗的耐药机制。
"We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration (FDA) to review patient study data," said Peter Nielsen, CEO of Bio-Path Holdings.
Bio-Path Holdings首席执行官彼得·尼尔森表示：“我们很高兴能够安全地完成第二个更高剂量的队列，达到美国食品药品监督管理局（FDA）审查患者研究数据的重要研究里程碑。”
"Enrollment rates have been good, and we look forward to advancing this study in even higher doses with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study with increased levels of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options," Nielsen added.
尼尔森补充说：“入学率一直不错，我们期待以更高的剂量推进这项研究，希望我们能够更快地进入1/1b期研究的联合疗法部分，提高用于治疗这些几乎没有治疗选择的脆弱患者的 BP1002 水平。”
Bio-Path shares are moving on heavy trading volume Thursday and have been halted for volatility. According to data from Benzinga Pro, more than 40 million shares have already been traded in the session, compared to the stock's 100-day average of less than 39,000 shares.
周四，Bio-Path的股票交易量居高不下，并因波动而暂停。根据Benzinga Pro的数据，该交易日已经交易了超过4000万股股票，而该股的100天平均交易量不到39,000股。
Related News: What's Going On With Arm Holdings Stock?
相关新闻： Arm Holdings 的股票怎么了？
How To Buy BPTH Stock:
如何购买 BPTH 股票：
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了前往经纪平台购买股票的股票（或部分股票）外，您还可以通过购买本身持有股票的交易所交易基金（ETF）来获得股票，或者将自己分配到401（k）中寻求收购共同基金或其他工具股票的策略。
For example, in Bio-Path's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，就Bio-Path而言，它属于医疗保健领域。ETF可能会持有许多有助于追踪该行业的流动性和大型公司的股票，从而使投资者能够了解该细分市场的趋势。
BPTH Price Action: According to Benzinga Pro, Bio-Path shares are up 67% at $5.41 at the time of publication Thursday.
BPTH价格走势：根据Benzinga Pro的数据，在周四发布时，Bio-Path股价上涨了67％，至5.41美元。
Image: Phoenix Locklear from Pixabay
图片：来自 Pixabay 的菲尼克斯·洛克利尔
译文内容由第三方软件翻译。